UTILITY PATENT APPLICATION TRANSMITTAL (Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No. 239770US0DIV

First Inventor or Application Identifier David LEWIS

Title PHARMACEUTICAL AEROSOL COMPOSITION

Assignee Name: Assignee Address:

CHIESI FARMACEUTICI S.p.A. Via Palermo, 26/A - Parma, Italy

APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents	Commissioner for Patents ADDRESS TO: Mail Stop Patent Application Alexandria, Virginia 22313					
1. Fee Transmittal Form (e.g. PTO/SB/17) (Submit an original and a duplicate for fee processing)	ACCOMPANYING APPLICATION PARTS					
(Cubinitian original differ a copied to not preceded by	7. Assignment Papers (cover sheet & document(s))					
2. Specification Total Sheets 35	8. Application Data Sheet. See 37 CFR 1.76					
	9. 37 C.F.R. §3.73(b) Statement Power of Attorney					
3. Drawing(s) (35 U.S.C. 113) Total Sheets	10. English Translation Document (if applicable)					
	11. Information Disclosure Statement (IDS)/PTO-1449 Copies of IDS Citations					
4. Oath or Declaration Total Pages 4	12. 3 7 CFR 1.604(a)(1) Amendment					
a. Newly executed (original or copy)	13. White Advance Serial No. Postcard					
b. Copy from a prior application (37 C.F.R. §1.6 (for continuation/divisional with box 17 completed)	14. Certified Copy of Priority Document(s) (if foreign priority is claimed)					
 i. DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) nather prior application, see 37 C.F.R. §1.63(d)(2) and 1.33(b). 						
5. CD-ROM or CD-R in duplicate, large table or Com Program (Appendix)	puter 16. Other: Request for Priority					
Nucleotide and/or Amino Acid Sequence Submissi	on 37 CFR 1.604 Request for an Interference with an Application					
6. (if applicable, all necessary)	(if applicable, all necessary)					
a. Computer Readable Form (CRF)						
b. Specification or Sequence Listing on :i. □ CD-ROM or CD-R (2 copies); or						
i. □ CD-ROM or CD-R (2 copies); or ii. □ Paper						
c. Statements verifying identity of above copies						
17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below: ☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application no.: 10/435,354						
☐ Continuation ☐ Divisional ☐ Continu Prior application information: Examiner:	n-in-part (CIP) of prior application no.: 10/435,354 Group Art Unit;					
For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.						
18. Amend the specification by inserting before the first line the sentence:						
■ This application is a ☐ Continuation ☐ Division						
of application Serial No. 10/435,354 Filed o	ay 12, 2003, pending, which is a Continuation of application Serial No. 1/796,607, filed March 2, 2001, now abandoned, which is a Continuation application Serial No. 09/147,669, filed February 24, 1999, now andoned, which is the National Stage of International Application No.					
☐ This application claims priority of provisional application	PCT/EP98/03533, filed June 10, 1998. Serial No. Filed					
	PONDENCE ADDRESS					
22850 (703) 413-3000 FACSIMILE: (703) 413-2220						
, ACOIMI						

Name:	Stephen G. Baxter, Ph.D.	Registration No.	32,884
Signature:	Start G But	Date	July 3, 2003
Name:		Registration No.	

Docket No.

239770US0DIV

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

INVENTOR(S) David LEWIS, et al.

SERIAL NO:

New Application

FILING DATE: Herewith

PHARMACEUTICAL AEROSOL COMPOSITION

FEE TRANSMITTAL

DMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

FOR	NUMBER FILED	NUMBER EXTRA	RATE	CALCULATIONS
TOTAL CLAIMS	22 - 20 =	2	x \$18 =	\$36.00
INDEPENDENT CLAIMS	3 - 3 =	0	x \$84 =	\$0.00
☐ MULTIPLE DEPENDEN	\$0.00			
☐ LATE FILING OF DECL	+ \$130 =	\$0.00		
	\$750.00			
	\$786.00			
☐ REDUCTION BY 50% F	\$0.00			
☐ FILING IN NON-ENGLISH LANGUAGE			+ \$130 =	\$0.00
☐ RECORDATION OF ASSIGNMENT			+ \$40 =	\$0.00
			TOTAL	\$786.00

- ☐ Please charge Deposit Account No. <u>15-0030</u> in the amount of **\$0.00** A duplicate copy of this sheet is enclosed.
- A check in the amount of \$786.00 to cover the filing fee is enclosed.
- The Director is hereby authorized to charge any additional fees which may be required for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to Deposit Account No. 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully Submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

July 3, 2003

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 05/03)

Stephen G. Baxter, Ph.D.

Registration No.

32,884